Search...
The first ever drug to treat dry age-related macular degeneration (AMD) was approved for use in the US earlier this year. The approval is welcome news to the 5 million people worldwide who suffer from this relentlessly progressive, vision-threatening, endstage form of dry AMD. But there are some important things for patients to know about the new treatment. In this segment of “Ask An Ophthalmologist,” Dr. Rahul Khurana addresses some of those issues. Speak with your ophthalmologist to find out if this new treatment is right for you. The FDA approved a second treatment for dry AMD a couple of weeks ago. Rahul N. Khurana, MD, FASRS is a vitreoretinal surgeon at Northern California Retina Vitreous Associates and clinical associate professor of ophthalmology at University of California at San Francisco. He also serves as the Academy’s Secretary for Online Education.
By aaoeye
Published
From the Health Care Hub community. Empowering medical learners with innovative insights for healthcare advancement.
Posted in Ophthalmologists 👁️. Explore innovative insights and empower medical learners for healthcare advancements.
8 views
1 likes